CADILA PHARMACEUTICALS LTD.
|CADILA PHARMACEUTICALS LTD. Patent applications|
|Patent application number||Title||Published|
|20120328574||P38 INHIBITORS - The invention relates to novel p38 MAPK inhibitor which involves||12-27-2012|
|20120308605||Pharmaceutical Composition of Killed Cells with Substantially Retained Immunogenicity - This invention discloses the process for lyophilisation of the treated cells which comprises the use of a solution containing Trehalose along with amphipathic polymer Polyvinylpyrrolidone. Further the invention discloses the process treating cancer cells, freezing, lyophilizing and reconstituting. Immunomodulator treated dead, but intact cancerous cells were recovered, which can subsequently be used for cancer immunotherapy.||12-06-2012|
|20120014985||Vaccine Adjuvants - The invention relates to a novel adjuvant||01-19-2012|
|20110183919||NOVEL DIPEPTIDYL PEPTIDASE IV (DP-IV) COMPOUNDS - The present invention is directed to novel compounds of formula I and pharmaceutically acceptable salts, enantiomers thereof having inhibiting properties of dipeptidyl peptidase IV enzyme (DP-IV inhibitors). The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds along with its composition in the prevention or treatment of diseases associated with DP-IV enzyme.||07-28-2011|
|20110182939||Vaccine Adjuvants - The invention provides novel adjuvants and pharmaceutical composition comprising of an adjuvant alone. The invention also provides novel vaccine compositions comprising of an antigen and a novel adjuvant. The novel adjuvant as per present invention is farnesoid-X-receptor (FXR) antagonist. The invention also relates to an adjuvant for variety of antigens. The adjuvant improves antibody production specific to incorporated antigen. The adjuvant also induces cell mediated immune response.||07-28-2011|
|20100209394||MITOGEN ACTIVATED PROTEIN KINASE MODULATOR - The present invention describes the method of modulating MAPK pathways. Further more the invention describes the use of Mycobacterium w for modulation of MAPK pathway intermediates for treatment of MAPK mediated conditions.||08-19-2010|
|20100062026||POLY TLR ANTAGONIST - w or its components are found to have poly TLR antagonistic activity to induced TLRs by varieties of TLR ligands. The induced TLR against which inhibitory effect is seen includes TLR 3, 4, 5, 6, 7, 8, 9. They also display antagonistic activities to effects of TLR ligands. They are also useful in management of diseases wherein TLRs are over expressed, like sepsis, multiple sclerosis, optic neuritis, Chronic obstructive pulmonary diseases multiple myeloma etc.||03-11-2010|
|20090177008||NOVEL PROCESS FOR SYNTHESIS OF ITOPRIDE AND ITS NOVEL INTERMEDIATE N-(4-HYDROXYBENZYL)- 3,4-DIMETHOXYBENZAMIDE - The present invention relates to a novel and improved process for the preparation of N-[4-[2-(dimethylamino)ethoxy]benzyl]-3,4-dimethoxybenzamide—known as Itopride, via a novel intermediate N-(4˜hydroxybenzyl)-3,4-dimethoxybenzamide.||07-09-2009|
Patent applications by CADILA PHARMACEUTICALS LTD.